Detailed Information on Publication Record
2014
Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle
GUMULEC, Jaromír, Jan BALVAN, Markéta SZTALMACHOVÁ, Martina RAUDENSKÁ, Veronika DVOŘÁKOVÁ et. al.Basic information
Original name
Cisplatin-resistant prostate cancer model: Differences in antioxidant system, apoptosis and cell cycle
Authors
GUMULEC, Jaromír (203 Czech Republic, belonging to the institution), Jan BALVAN (203 Czech Republic, belonging to the institution), Markéta SZTALMACHOVÁ (203 Czech Republic, belonging to the institution), Martina RAUDENSKÁ (203 Czech Republic, belonging to the institution), Veronika DVOŘÁKOVÁ (203 Czech Republic, belonging to the institution), Lucia KNOPFOVÁ (203 Czech Republic, belonging to the institution), Hana POLANSKÁ (203 Czech Republic, belonging to the institution), Kristýna HUDCOVÁ (203 Czech Republic, belonging to the institution), Branislav RUTTKAY-NEDECKÝ (203 Czech Republic), Petr BABULA (203 Czech Republic), Vojtěch ADAM (203 Czech Republic), René KIZEK (203 Czech Republic), Marie STIBOROVÁ (203 Czech Republic) and Michal MASAŘÍK (203 Czech Republic, guarantor, belonging to the institution)
Edition
International Journal of Oncology, University of Crete, Faculty of Medicine, Laboratory of Clinical Virology, 2014, 1019-6439
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30105 Physiology
Country of publisher
Greece
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 3.025
RIV identification code
RIV/00216224:14110/14:00075570
Organization unit
Faculty of Medicine
UT WoS
000336894900034
Keywords in English
Cell cycle; Cisplatin; Oxidative stress; Prostate cancer; Resistance
Tags
International impact, Reviewed
Změněno: 8/7/2014 16:16, Ing. Mgr. Věra Pospíšilíková
Abstract
V originále
Differences in the antioxidant system, apoptotic mechanism and in cell cycle between prostatic cell lines could partially elucidate the development of cisplatin resistance. The aim of this study was to identify the most characteristic parameter for a particular cell line and/or a particular cisplatin treatment using a general regression model and to assess whether it is possible to use measured parameters as markers of cisplatin resistance. This study integrates the results of viability, antioxidant, flow cytometric and quantitative PCR assays in order to characterize the resistance of prostate cancer to cisplatin. Cell growth using metabolic- (MTT) and impedance-based assays, the expression of key cell death signaling proteins (p53, Bax and Bcl-2), cell cycle, activity of antioxidant system-related proteins (superoxide dismutase, glutathione peroxidase, glutathione reductase and metallothionein) and free radical scavenging capacity assays [free radicals (FR), ferric reducing antioxidant power (FRAP), ABTS] were analyzed in the cell lines 22Rv1, PC-3 and PNT1A with respect to rising concentrations and different length of cisplatin treatment (12-72 h). The non-functional-p53 PC-3 cell line showed decreased BAX (p<0.05) and, in contrast to PNT1A and 22Rv1, no cisplatin-induced effects on cell cycle. All cell lines showed increasing levels of free radical scavenging activity by ABTS, FRAP and FR assays in a time- and dose-dependent manner (r>0.76 at p<0.001 for ABTS, FRAP and FR at p<0.001). PC-3 showed increased (p<0.05) levels of free radical scavenging activity by ABTS and FR methods. These findings, together with significantly elevated MT, decreased p53 and Bax indicate PC-3 to be cisplatin-resistant. The differences in the antioxidant system and apoptotic mechanisms in PC-3 cells may elucidate the development of cisplatin resistance and indicate that this cell line may be further studied as a model of cytostatic resistance.
Links
ED1.1.00/02.0068, research and development project |
| |
EE2.3.20.0183, research and development project |
|